Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, Minnesota 55902


CABANA is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing total mortality (primary endpoint) and decreasing the composite endpoint of total mortality, disabling stroke, serious bleeding and cardiac arrest (secondary endpoint) in patients with untreated or incompletely treated AF warranting therapy.

Study summary:

The need for this trial arises out of 1) the rapidly increasing number of pts > 60 years of age with AF accompanied by symptoms and morbidity, 2) the failure of anti-arrhythmic drug therapy to maintain sinus rhythm and reduce mortality, 3) the rapidly increasing application of radio-frequency catheter ablation without appropriate evidence-based validation, and 4) the expanding impact of AF on health care costs. This study will randomize patients to a strategy of catheter ablation versus pharmacologic therapy with rate or rhythm control drugs. Each pt will have 1) characteristics similar to AFFIRM pts (>65 yo or <65 with >1 risk factor for stroke, 2) Documented AF warranting treatment, and 3) Eligibility for both catheter ablation and >2 anti-arrhythmic or >3 rate control drugs. Pts will be followed every 6 months for >2 yrs and will undergo repeat trans-telephonic monitor, Holter monitor, and CT/MR studies to assess the impact of treatment. The CABANA trial will disclose the role of medical and non-pharmacologic therapies for AF, establish the cost and impact of therapy on quality of life and will help determine if AF is a modifiable risk factor for increased mortality.


Inclusion Criteria: - Have documented AF, which warrants active drug or ablative treatment - Be eligible for both catheter ablation and at least 2 sequential anti-arrhythmic drugs and/or 3 sequential rate control drugs - Be >65 yrs of age, or <65 yrs with one or more of the following risk factors for stroke: Hypertension, Diabetes, Congestive heart failure (including systolic or diastolic heart failure), Prior stroke or TIA, Left atrium >4.5 cm, EF <35% by echocardiogram, radionuclide evaluation or contrast ventriculography Exclusion Criteria: - Previously failed 2 or more membrane active anti-arrhythmic drugs - Efficacy failure of a full dose Amiodarone trial of >12 weeks duration - Any amiodarone therapy in the past three months - Reversible causes of AF including thyroid disorders, acute alcohol intoxication, recent major surgical procedures, or trauma - Lone atrial fibrillation in the absence of risk factors for stroke in patients <65 years of age - Recent cardiac events including MI, PCI, or valve or coronary bypass surgery in the preceding 3 months - Hypertrophic obstructive cardiomyopathy - Class IV angina or congestive heart failure - Planned heart transplantation - Other mandated anti-arrhythmic drug therapy - Heritable arrhythmias or increased risk for torsade de pointes with class I or III drugs - Prior LA catheter ablation with the intention to treat AF - Patients with other arrhythmias requiring ablative therapy - Prior surgical interventions for AF such as the MAZE procedure - Prior AV nodal ablation - Medical conditions limiting expected survival to <1 year - Contraindication to warfarin anti-coagulation - Women of childbearing potential - Participation in any other clinical mortality trial - Unable to give informed consent



Primary Contact:

Principal Investigator
Douglas L. Packer, M.D.
Mayo Clinic

Backup Contact:


Location Contact:

Rochester, Minnesota 55902
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.